# Ensoma Startup profile on Capital Atlas: https://capitalatlas.ai/startups/ensoma - Industry: Biotechnology - Headquarters: Boston, US - Website: www.ensoma.com - Total disclosed funding: $215M - Latest round: Series B (Sep 22, 2025) - Investors on record: 21 ## About Ensoma, Inc. is a Boston-based biotechnology company focused on in vivo hematopoietic stem cell engineering, aiming to develop innovative one-time therapies for genetic, immune, and oncological diseases.Founded in 2019 and headquartered in Boston, US, Ensoma specializes in advanced biotechnology solutions. The company raised USD 50 mn in a Series B funding round on May 22, 2023, led by Kite Pharma, Inc., which brought the total amount raised to USD 50 mn. Andre Lieber is the founder, who has prior experience in the biotechnology sector.Ensoma specializes in advanced in vivo hematopoietic stem cell (HSC) engineering technology. The company's core offerings center around a comprehensive platform that integrates an off-the-shelf delivery system with a sophisticated gene engineering toolkit. This platform enables the precise and durable modification of cells within the entire hematopoietic system, targeting various diseases through a one-time therapy approach. Ensoma's innovative treatments aim to address genetic, immune, and oncological diseases, significantly enhancing the patient experience by providing simple, fast, and safe solutions. The primary end users of these therapies include patients suffering from hematological disorders, while healthcare providers and institutions serve as the main client base, primarily in North America and select markets in Europe and Asia.Ensoma's revenue model is centered around partnerships and collaborations with healthcare providers, research institutions, and pharmaceutical companies. The company engages in direct transactions with clients who seek its innovative HSC engineering solutions for therapeutic applications. These arrangements may involve licensing agreements or joint development partnerships, allowing for tailored solutions that meet specific client needs. The flagship offerings, facilitated through this model, include proprietary gene editing technologies that are delivered as comprehensive treatment solutions. Revenue generation occurs through these strategic collaborations, enabling Ensoma to leverage its advanced technology in addressing critical medical challenges while supporting the growth and sustainability of its business initiatives.In May 2023, Ensoma, Inc. raised USD 50 mn in Series B funding, part of a larger USD 135 mn round, to advance its breakthrough therapies toward clinical application. The company plans to utilize this funding to support the development of new products and therapies targeting hematological disorders. Ensoma is also looking to expand its operations into new geographic markets, including Europe and Asia, by the end of 2024, aiming to increase accessibility to its innovative treatments. In September 2025, Ensoma, Inc. raised USD 53 million in venture funding from new investors Gilead Sciences, Inc., Hanwha Impact Partners, and RTW Investments, with participation from returning investors 5AM Ventures, Bill & Melinda Gates Foundation, Catalio Capital Management, Cormorant Asset Management, Delos Capital Management, F-Prime Capital, Mirae Asset Global Investments, Qatar Investment Authority, Solasta Ventures, SymBiosis LLC, and Viking Global Investors. The company will use the funding to advance clinical testing of its gene therapy for chronic granulomatous disease and continue developing stem cell-based treatments. ## Funding rounds - Series B, Sep 22, 2025, $45M — 5AM Ventures, Mirae Asset Global Investments, F-Prime Capital, Viking Global Investors, Qatar Investment Authority, Gilead Sciences, Inc., Bill & Melinda Gates Foundation, RTW Investments, Delos Capital, Cormorant Asset Management, SymBiosis LLC, Solasta Ventures, Catalio Capital Management, Hanwha Impact Partners - Series B, May 22, 2023, $50M — Kite Pharma, Inc., Delos Capital, SymBiosis LLC, Bioluminescence Ventures - Series B, Dec 23, 2022, $79M — Alexandria Venture Investments, 5AM Ventures, Mirae Asset Global Investments, F-Prime Capital, Viking Global Investors, Qatar Investment Authority, Bill & Melinda Gates Foundation, Takeda Ventures, Cormorant Asset Management, Fred Hutchinson Cancer Research Center, Arix Bioscience, SymBiosis LLC, Solasta Ventures, Catalio Capital Management - Series A, Feb 11, 2021, $41M — Alexandria Venture Investments, 5AM Ventures, F-Prime Capital, Viking Global Investors, RIT Capital Partners, Takeda Ventures, Cormorant Asset Management, SymBiosis LLC - Seed, Jun 1, 2019 — 5AM Ventures ## Investors - 5AM Ventures (https://capitalatlas.ai/funds/5am-ventures) — Seed, Series A, Series B - Alexandria Venture Investments (https://capitalatlas.ai/funds/alexandria-venture-investments) — Series A, Series B - F-Prime Capital (https://capitalatlas.ai/funds/f-prime-capital) — Series A, Series B - Viking Global Investors (https://capitalatlas.ai/funds/viking-global-investors) — Series A, Series B - RIT Capital Partners — Series A - Takeda Ventures (https://capitalatlas.ai/funds/takeda-ventures) — Series A, Series B - Cormorant Asset Management (https://capitalatlas.ai/funds/cormorant-asset-management) — Series A, Series B - SymBiosis LLC — Series A, Series B - Mirae Asset Global Investments (https://capitalatlas.ai/funds/mirae-asset-global-investments) — Series B - Qatar Investment Authority (https://capitalatlas.ai/funds/qatar-investment-authority) — Series B - Bill & Melinda Gates Foundation — Series B - Fred Hutchinson Cancer Research Center — Series B - Arix Bioscience (https://capitalatlas.ai/funds/arix-bioscience) — Series B - Solasta Ventures (https://capitalatlas.ai/funds/solasta-ventures) — Series B - Catalio Capital Management (https://capitalatlas.ai/funds/catalio-capital-management) — Series B - Kite Pharma, Inc. — Series B - Delos Capital (https://capitalatlas.ai/funds/delos-capital) — Series B - Bioluminescence Ventures (https://capitalatlas.ai/funds/bioluminescence-ventures) — Series B - Gilead Sciences, Inc. — Series B - RTW Investments (https://capitalatlas.ai/funds/rtw-investments) — Series B - Hanwha Impact Partners (https://capitalatlas.ai/funds/hanwha-impact-partners) — Series B